AI Engines For more Details: Perplexity Kagi Labs You
Asthma and COPD: Clenbuterol hydrochloride is a beta-2 adrenergic agonist that works by relaxing the smooth muscles of the airways, thereby dilating the bronchioles and improving airflow into the lungs. It is used as a bronchodilator to relieve symptoms such as wheezing, shortness of breath, and chest tightness in individuals with asthma and chronic obstructive pulmonary disease (COPD).
Bronchospasm: Clenbuterol hydrochloride may also be used to prevent exercise-induced bronchospasm (EIB) in individuals with asthma or exercise-induced asthma. By dilating the airways, clenbuterol helps to reduce the risk of bronchospasm and improve exercise tolerance in susceptible individuals.
Off-label Uses: Clenbuterol hydrochloride is sometimes used off-label for its potential anabolic effects in bodybuilding and athletic performance enhancement. It is believed to increase muscle mass and reduce body fat by stimulating beta-2 adrenergic receptors in skeletal muscle tissue, leading to enhanced protein synthesis and lipolysis. However, the use of clenbuterol for these purposes is controversial and carries significant risks of adverse effects and legal consequences.
Side Effects: Clenbuterol hydrochloride may cause a range of side effects, including tremors, palpitations, tachycardia (rapid heartbeat), headaches, nervousness, insomnia, and sweating. These side effects are primarily due to its stimulant properties and may be more pronounced at higher doses. Clenbuterol may also increase blood pressure and have cardiac effects, which can be particularly concerning in individuals with underlying cardiovascular conditions.
Tolerance and Dependence: Prolonged use of clenbuterol hydrochloride may lead to tolerance, meaning that higher doses are required to achieve the same bronchodilator effect. Additionally, abrupt discontinuation of clenbuterol after long-term use may result in withdrawal symptoms, including rebound bronchoconstriction, fatigue, and mood changes.
Legal Status: Clenbuterol hydrochloride is classified as a performance-enhancing drug (PED) and is banned by most sports organizations, including the World Anti-Doping Agency (WADA) and the International Olympic Committee (IOC). Its use without a prescription is illegal in many countries due to concerns about its potential for misuse and abuse.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.3 | 0.5 | -0.67 |
ADHD | 3.9 | 0.6 | 5.5 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
Allergic Rhinitis (Hay Fever) | 1.9 | 1.7 | 0.12 |
Allergies | 3.7 | 2.4 | 0.54 |
Allergy to milk products | 1.2 | 0.6 | 1 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 3.3 | 3.5 | -0.06 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.4 | 2.25 |
Ankylosing spondylitis | 2.2 | 0.7 | 2.14 |
Anorexia Nervosa | 1.2 | 2.3 | -0.92 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 3.8 | 2.3 | 0.65 |
Atherosclerosis | 1.2 | 1 | 0.2 |
Atrial fibrillation | 2.5 | 0.7 | 2.57 |
Autism | 5.1 | 4.5 | 0.13 |
Autoimmune Disease | 0.6 | 1 | -0.67 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.3 | -0.3 | |
Biofilm | 0.8 | 0.8 | |
Bipolar Disorder | 1.1 | 1.4 | -0.27 |
Brain Trauma | 0.9 | 1.4 | -0.56 |
Cancer (General) | 0.6 | 1.7 | -1.83 |
Carcinoma | 2.7 | 2.2 | 0.23 |
Celiac Disease | 1.2 | 2.7 | -1.25 |
Cerebral Palsy | 1.4 | 1.3 | 0.08 |
Chronic Fatigue Syndrome | 3.8 | 3.3 | 0.15 |
Chronic Kidney Disease | 2.4 | 1.2 | 1 |
Chronic Lyme | 0.2 | 0.8 | -3 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 1.1 | -0.57 |
Chronic Urticaria (Hives) | 0.8 | 0.1 | 7 |
Coagulation / Micro clot triggering bacteria | 0.3 | 1.3 | -3.33 |
Cognitive Function | 3.2 | 1.6 | 1 |
Colorectal Cancer | 3.9 | 1.9 | 1.05 |
Constipation | 0.6 | 0.7 | -0.17 |
Coronary artery disease | 1.3 | 1.7 | -0.31 |
COVID-19 | 6.3 | 7.2 | -0.14 |
Crohn's Disease | 4.1 | 3 | 0.37 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 1.7 | -1.7 | |
deep vein thrombosis | 1 | 1.4 | -0.4 |
Denture Wearers Oral Shifts | 0.9 | 0.9 | |
Depression | 6 | 5.4 | 0.11 |
Dermatomyositis | 0.3 | 0.3 | 0 |
Eczema | 0.9 | 1.3 | -0.44 |
Endometriosis | 1.6 | 1.4 | 0.14 |
Eosinophilic Esophagitis | 0.6 | -0.6 | |
Epilepsy | 1.6 | 0.9 | 0.78 |
erectile dysfunction | 0.8 | 0.3 | 1.67 |
Fibromyalgia | 2.2 | 0.9 | 1.44 |
Functional constipation / chronic idiopathic constipation | 2.7 | 2.1 | 0.29 |
gallstone disease (gsd) | 1.6 | 0.9 | 0.78 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.9 | -2 |
Generalized anxiety disorder | 1.2 | 2.2 | -0.83 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 1.5 | 0.6 | 1.5 |
Graves' disease | 1.5 | 3 | -1 |
Gulf War Syndrome | 0.6 | 0.8 | -0.33 |
Halitosis | 0.9 | 0.3 | 2 |
Hashimoto's thyroiditis | 2.7 | 0.8 | 2.38 |
Heart Failure | 1.4 | 1.5 | -0.07 |
hemorrhagic stroke | 0.6 | 0.6 | |
Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
High Histamine/low DAO | 1 | 0.6 | 0.67 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
hyperglycemia | 1.2 | 0.9 | 0.33 |
Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 2.6 | 3.6 | -0.38 |
Hypothyroidism | 0.1 | 0.7 | -6 |
Hypoxia | 1.6 | 0.3 | 4.33 |
IgA nephropathy (IgAN) | 1.2 | 3.1 | -1.58 |
Inflammatory Bowel Disease | 4.2 | 5.6 | -0.33 |
Insomnia | 1.6 | 2.3 | -0.44 |
Intelligence | 0.7 | 0.7 | |
Intracranial aneurysms | 0.7 | 0.6 | 0.17 |
Irritable Bowel Syndrome | 4.9 | 3.4 | 0.44 |
ischemic stroke | 2.2 | 1.1 | 1 |
Liver Cirrhosis | 4.6 | 3.6 | 0.28 |
Long COVID | 3.4 | 5.8 | -0.71 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.2 | 1.1 | -4.5 |
Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
ME/CFS with IBS | 0.6 | 1.5 | -1.5 |
ME/CFS without IBS | 1.2 | 1.5 | -0.25 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 1.8 | 0.6 | 2 |
Metabolic Syndrome | 4.2 | 5 | -0.19 |
Mood Disorders | 6.2 | 4.4 | 0.41 |
multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
Multiple Sclerosis | 3.8 | 2.7 | 0.41 |
Multiple system atrophy (MSA) | 0.4 | 0.7 | -0.75 |
myasthenia gravis | 0.3 | 0.7 | -1.33 |
neuropathic pain | 0.3 | 1.6 | -4.33 |
Neuropathy (all types) | 0.8 | 1.1 | -0.38 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 3.7 | -0.03 |
NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
Obesity | 5.9 | 5.4 | 0.09 |
obsessive-compulsive disorder | 2.8 | 2.6 | 0.08 |
Osteoarthritis | 1.4 | 1.2 | 0.17 |
Osteoporosis | 1.9 | 1.4 | 0.36 |
pancreatic cancer | 0.6 | 0.3 | 1 |
Parkinson's Disease | 5.2 | 3.5 | 0.49 |
Polycystic ovary syndrome | 3.2 | 2.8 | 0.14 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 0.7 | 0.7 | |
primary biliary cholangitis | 1.2 | 0.9 | 0.33 |
Primary sclerosing cholangitis | 1.7 | 1.4 | 0.21 |
Psoriasis | 2.3 | 1.1 | 1.09 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 3 | 0.63 |
Rosacea | 0.8 | 1 | -0.25 |
Schizophrenia | 4.7 | 2.1 | 1.24 |
scoliosis | 0.3 | -0.3 | |
Sjögren syndrome | 1.6 | 2.2 | -0.38 |
Sleep Apnea | 1.3 | 1.6 | -0.23 |
Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.5 | 1.2 |
Stress / posttraumatic stress disorder | 2 | 1.8 | 0.11 |
Systemic Lupus Erythematosus | 1.9 | 1.6 | 0.19 |
Tic Disorder | 0.9 | 1.2 | -0.33 |
Tourette syndrome | 0.9 | 0.3 | 2 |
Type 1 Diabetes | 2.2 | 3.2 | -0.45 |
Type 2 Diabetes | 4.4 | 4.8 | -0.09 |
Ulcerative colitis | 2.4 | 3.5 | -0.46 |
Unhealthy Ageing | 2.4 | 1.3 | 0.85 |
Vitiligo | 1.2 | 0.6 | 1 |